Both in vitro and in vivo experiments have demonstrated that CD133+ stem-like cells represent a prominent subpopulation within gastric cancer, and the gene poly[ADP-ribose] polymerase 1 (PARP1) plays a central role in mediating resistance to oxaliplatin. The gene discussed is PARP1; the disease is gastric cancer.